Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$45.06 - $67.74 $6.31 Million - $9.48 Million
-140,000 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$37.13 - $74.62 $5.2 Million - $10.4 Million
140,000 New
140,000 $10 Million

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Slate Path Capital LP Portfolio

Follow Slate Path Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Slate Path Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Slate Path Capital LP with notifications on news.